Allergan plc

If you purchased Allergan plc securities and would like to join the action, please click "Join This Action" below.

ALLERGAN MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ALLERGAN PLC IS FAIR TO SHAREHOLDERS – AGN

June 25, 2019.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Allergan plc (NYSE: AGN) to AbbVie Inc. (“AbbVie”) is fair to Allergan shareholders. On behalf of Allergan shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

The Allergan merger investigation concerns whether Allergan and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Allergan shareholders; (2) determine whether AbbVie is underpaying for Allergan; and (3) disclose all material information necessary for Allergan shareholders to adequately assess and value the merger consideration.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

 

Certification

Scroll to Top